José Ruiz-Cantador

José Ruiz-Cantador

Auto-generated profile, based on publicly available information

José Ruiz-Cantador

Cardiology Department, University Hospital La Paz (C.A.A.-O., T.G.-F., L.C.-M., S.G.-E., J.D.-D., A.E.G.-G., J.R.-C., P.M.-C., C.M.-A., N.G.R., R.M.-G., R.P.-P.).

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2025 in Cancer Discovery
Verified
Journal Article
Open access
CACarlota Arenillas
Carlota Arenillas
LCLucía Celada
Lucía Celada
JRJosé Ruiz-Cantador
José Ruiz-Cantador
BCBruna Calsina
Bruna Calsina
DDDebayan Datta
Debayan Datta
RTRodrigo Toledo
Rodrigo Toledo
This study explores parallels between systemic hypoxia adaptation in high-altitude populations and tumorigenesis. We identified EPAS1, a gene critical for hypoxia adaptation in populations such as Tibetans and Sherpas, as playing a similar adaptive role in tumors arising under hypoxic conditions. Tumors from patients with chronic hypoxia displayed impaired DNA repair and frequent emergence of EPAS1 variants, with frequencies reaching up to 90%, echoing the positive selection seen in high-altitude dwellers. Mechanistically, EPAS1 gain-of-function mutations promote COX4I2 expression, reducing cellular oxygen consumption and supporting tumor proliferation in hypoxia. Analysis of clinical data from patients with hypoxia revealed tissue-specific and time-sensitive tumorigenic effects, particularly impacting oxygen-sensitive cells in the postnatal period. Our findings suggest that EPAS1-driven adaptation mechanisms in high-altitude populations provide a model for understanding tumor evolution under hypoxic stress, highlighting how genetic adaptations to diverse stressors in natural populations may yield insights into tumorigenesis and cancer progression. Significance: This study reveals a broad convergence in genetic adaptation to hypoxia between natural populations and tumors, suggesting that insights from natural populations could enhance our understanding of cancer biology and identify novel therapeutic targets. See related commentary by Lee, p. 875

26 December 2024 in Revista de ecocardiografía práctica y otras técnicas de imagen cardíaca
Verified
Journal Article
Open access
PDF file
PAPedro María Azcárate Agüero
Pedro María Azcárate Agüero
JRJosé Ruiz-Cantador
José Ruiz-Cantador
La resonancia magnética cardíaca (RMC) se ha consolidado como una buena técnica para la evaluación anatómica y funcional del septo interauricular (SIA), permitiendo detectar alteraciones como defectos septales (comunicación interauricular [CIA]) y otras anomalías relacionadas. Aquí presentamos un protocolo optimizado para obtener imágenes de alta calidad mediante secuencias de cine con el objetivo de realizar un diagnóstico preciso.

1 September 2026 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
CÁCarlos A. Álvarez-Ortega
Carlos A. Álvarez-Ortega
TGTeba González-Ferrero
Teba González-Ferrero
LCLucía Canales-Muñoz
Lucía Canales-Muñoz
SGSoraya González-Estriégana
Soraya González-Estriégana
JDJesús Diz-Díaz
Jesús Diz-Díaz
RPRafael Peinado
Rafael Peinado
BACKGROUND: Reentrant atrial tachycardias (ATs) are frequent after atrial switch for dextro-transposition of the great arteries and are associated with adverse prognosis. Catheter ablation is first-line therapy, yet long-term outcomes and predictors of recurrence remain poorly defined. Our aim was to characterize induced AT circuits, describe acute and long-term catheter ablation outcomes, and identify recurrence predictors in dextro-transposition of the great arteries. METHODS: Single-center ambispective cohort of consecutive adults with dextro-transposition of the great arteries undergoing a first AT ablation (2003–2025). Arrhythmias were mechanically induced with decremental pacing or extra stimuli. Acute success was defined as elimination of all clinical and reproducibly inducible tachycardias (cycle length >200 ms), with bidirectional cavotricuspid isthmus block when applicable. Recurrence was defined as any documented AT >30 seconds. RESULTS: Thirty-three patients underwent 46 procedures. During the index procedure, 66 ATs were induced; 51 (83%) were characterized: 32 (63%) were cavotricuspid isthmus-dependent and 11 (22%) incisional. Cavotricuspid isthmus block was achieved in 84%; acute noninducibility in 73%. Median follow-up was 7.0 years (interquartile range, 2.5–10.4). Overall, 15 patients (45.5%) recurred; 1-year freedom was 75%. Recurrence was strongly associated with failed or uncertain acute efficacy, severely impaired systemic right ventricular fractional shortening ≤22%, prolonged PR interval (220 ms), and greater number of inducible ATs (all P <0.05). In multivariable modelling, these 4 variables yielded an optimism-corrected C-index of 0.85. Eleven (33%) underwent redo ablation; 8 achieved acute noninducibility, and only 3 recurred thereafter. CONCLUSIONS: In dextro-transposition of the great arteries postatrial switch, cavotricuspid isthmus-dependent flutter is most common, but scar-related circuits are frequent. Catheter ablation is safe and acutely effective, but long-term recurrence remains substantial. Failed acute efficacy, severely impaired systemic right ventricle contractility, prolonged PR interval, and multiple inducible ATs identify patients at highest risk and may guide follow-up and referral for early repeat ablation.

2 May 2025
Verified
Other
Open access
CACarlota Arenillas
Carlota Arenillas
LCLucía Celada
Lucía Celada
JRJosé Ruiz-Cantador
José Ruiz-Cantador
BCBruna Calsina
Bruna Calsina
DDDebayan Datta
Debayan Datta
RTRodrigo Toledo
Rodrigo Toledo
Supplementary Figure S1. Description of the CCHD-PPGL cohort of 27 individuals with CCHD who developed 38 PPGL tumors. Supplementary Figure S2. Summary of the clinical features of patients with CCHD-PPGL. Supplementary Figure S3. EPAS1 mutations are enriched in the hypoxic cohort of patients with CCHD-PPGL (88.8%) compared to the normoxic cohort of patients without CCHD-PPGL (4.5%). Supplementary Figure S4. EPAS1 clonality in PPGL tumor samples from TCGA(1–4) (patients without CCHD with PPGL in normoxic conditions). Supplementary Figure S5. No EPAS1 mutations were detected in carotid body PGL tumors. Supplementary Figure S6. Hierarchical cluster analysis of RNA sequencing data from EPAS1-mutated CCHD-PPGL tumors. Supplementary Figure S7. Convergent Evolution in Natural Populations and Human Tumors. Supplementary Figure S8. Evolutionary speed of EPAS1 selection in different cohorts. Supplementary Figure S9. Hematoxylin and eosin staining and immunohistochemistry for Chromogranin A (neuroendocrine tumors maker) and for mismatch repair (MMR) proteins in PPGL tumors. Supplementary Figure S10. Acquisition of EPAS1 mutation and subsequent selection in sympathetic PPGL tumors developed under systemic hypoxia. Supplementary Figure S11. Assessment of apoptosis marker in pheochromocytoma-derived cells upon expression of mutant EPAS1 genes or exposure to hypoxic conditions. Supplementary Figure S12. Increase levels of fumarate metabolite in EPAS1MUT PPGL tumors and increase levels of succinate metabolite in SDHxMUT PPGL tumors. Supplementary Figure S13. Decrease of fumarate hydratase/fumarase (FH) mRNA expression and increment of SDHB mRNA expression in EPAS1MUT/VHLMUT PPGL tumors when compared to EPAS1WT/VHLWT PPGL tumors, as well as to SDHxMUT PPGL tumors. Supplementary Figure S14. Decrease of FH mRNA expression in missense EPAS1-mutated tumors (n = 8) when compared to EPAS1-wild-type tumors (n = 170). Supplementary Figure S15. Elevated fumarate and succinate levels in EPAS1-Overexpressing PPGL cells. Supplementary Figure S16. Oxygen consumption and supply balance in the mitochondrial electron transport chain as an advantageous survival and proliferative mechanism. Supplementary Figure S17. Gene-level extremely positive selection on EPAS1 gene in systemic hypoxia. Supplementary Figure S18. Time-dependent effects of systemic hypoxia on oxygen-sensing tissues. Supplementary Figure S19. Specialization process of the HIF2α gene for adaptation to systemic hypoxia. Supplementary Figure S20. Proliferative advantage and increased sensitivity to HIF2α inhibition in HEK293T cells expressing the EPAS1 P405A/P531A double mutant. Supplementary Figure S21. Authentication of PPGL-derived PC12 cell line. Supplementary Figure S22. Full western blots shown in Fig. 3B. Supplementary Figure S23. Full western blots shown in Supplementary Fig S11.

17 June 2026
Verified
Other
Open access
CACarlota Arenillas
Carlota Arenillas
LCLucía Celada
Lucía Celada
JRJosé Ruiz-Cantador
José Ruiz-Cantador
BCBruna Calsina
Bruna Calsina
DDDebayan Datta
Debayan Datta
RTRodrigo Toledo
Rodrigo Toledo
Supplementary Tables Supplementary Table S1. Clinical and Tumoral Data from CCHD-PPGL patients. Supplementary Table S2. Selection inference in the PPGL (TCGA, non-CCHD) and CCHD-PPGL cohort. Supplementary Table S3. Cancer Cell Fraction of EPAS1 mutations in CCHD-PPGL and PPGL patients. Supplementary Table S4. Clonal Clustering of CCHD-PPGL tumor mutations, highlighting EPAS1 mutation, using Conipher. Supplementary Table S5. Clonal Clustering of PPGL tumor mutations (TCGA), highlighting EPAS1 mutation, using Conipher. Supplementary Table S6. Parallelism of EPAS1 genetic variant selection in high-altitude populations and human tumors. Supplementary Table S7. EPAS1 Frequencies of Denisovan AGGAA haplotype from 4,000 Han Chinese Population (https://www.biosino.org/pgghan2/index) compared with gnomAD cohort around the world. Supplementary Table S8. Genetic Instability Characteristics (MSI, CNA, TMB) from CCHD-PPGL and PPGL (TCGA) tumors. Supplementary Table S9. Data of 354 differentially expressed mitochondrial genes (from Human Mitocarta Database) between EPAS1MUT and EPAS1WT samples in patients with PPGL (TCGA). Supplementary Table S10. Gene expression profiling analysis from patients with hemoglobin disorders and 52 paragangliomas with various genotypes including 19 EPAS1 (including one tumor in duplicate), 6 SDHx, 2 SLC25A11, 6 VHL, 3 RET, 3 NF1, 1 MAX, 1 MAML3 and 11 unmutated paragangliomas (Mancini M et al. Br J Haematol, 2023). Supplementary Table S11. RNAseq Raw Counts from PC12 Cell line cultured under normoxia/hypoxia conditions. Supplementary Table S12. Tumor type and hypoxia onset in patients with CCHD-PPGL. Supplementary Table S13. O2 Saturation in CCHD patients with or without PPGL tumors. Supplementary Table S14. Heart surgery influence in tumor development in patients with CCHD-PPGL. Supplementary Table S15. Clinical features of tumors developed under hypoxia (CCHD-PPGL) and normoxia (non-CCHD-PPGL). Supplementary Table S16. Representation of clinical variables in patients with PPGL and CCHD-PPGL.

17 June 2026
Verified
Other
Open access
CACarlota Arenillas
Carlota Arenillas
LCLucía Celada
Lucía Celada
JRJosé Ruiz-Cantador
José Ruiz-Cantador
BCBruna Calsina
Bruna Calsina
DDDebayan Datta
Debayan Datta
RTRodrigo Toledo
Rodrigo Toledo
Supplementary Figure S1. Description of the CCHD-PPGL cohort of 27 individuals with CCHD who developed 38 PPGL tumors. Supplementary Figure S2. Summary of the clinical features of patients with CCHD-PPGL. Supplementary Figure S3. EPAS1 mutations are enriched in the hypoxic cohort of patients with CCHD-PPGL (88.8%) compared to the normoxic cohort of patients without CCHD-PPGL (4.5%). Supplementary Figure S4. EPAS1 clonality in PPGL tumor samples from TCGA(1–4) (patients without CCHD with PPGL in normoxic conditions). Supplementary Figure S5. No EPAS1 mutations were detected in carotid body PGL tumors. Supplementary Figure S6. Hierarchical cluster analysis of RNA sequencing data from EPAS1-mutated CCHD-PPGL tumors. Supplementary Figure S7. Convergent Evolution in Natural Populations and Human Tumors. Supplementary Figure S8. Evolutionary speed of EPAS1 selection in different cohorts. Supplementary Figure S9. Hematoxylin and eosin staining and immunohistochemistry for Chromogranin A (neuroendocrine tumors maker) and for mismatch repair (MMR) proteins in PPGL tumors. Supplementary Figure S10. Acquisition of EPAS1 mutation and subsequent selection in sympathetic PPGL tumors developed under systemic hypoxia. Supplementary Figure S11. Assessment of apoptosis marker in pheochromocytoma-derived cells upon expression of mutant EPAS1 genes or exposure to hypoxic conditions. Supplementary Figure S12. Increase levels of fumarate metabolite in EPAS1MUT PPGL tumors and increase levels of succinate metabolite in SDHxMUT PPGL tumors. Supplementary Figure S13. Decrease of fumarate hydratase/fumarase (FH) mRNA expression and increment of SDHB mRNA expression in EPAS1MUT/VHLMUT PPGL tumors when compared to EPAS1WT/VHLWT PPGL tumors, as well as to SDHxMUT PPGL tumors. Supplementary Figure S14. Decrease of FH mRNA expression in missense EPAS1-mutated tumors (n = 8) when compared to EPAS1-wild-type tumors (n = 170). Supplementary Figure S15. Elevated fumarate and succinate levels in EPAS1-Overexpressing PPGL cells. Supplementary Figure S16. Oxygen consumption and supply balance in the mitochondrial electron transport chain as an advantageous survival and proliferative mechanism. Supplementary Figure S17. Gene-level extremely positive selection on EPAS1 gene in systemic hypoxia. Supplementary Figure S18. Time-dependent effects of systemic hypoxia on oxygen-sensing tissues. Supplementary Figure S19. Specialization process of the HIF2α gene for adaptation to systemic hypoxia. Supplementary Figure S20. Proliferative advantage and increased sensitivity to HIF2α inhibition in HEK293T cells expressing the EPAS1 P405A/P531A double mutant. Supplementary Figure S21. Authentication of PPGL-derived PC12 cell line. Supplementary Figure S22. Full western blots shown in Fig. 3B. Supplementary Figure S23. Full western blots shown in Supplementary Fig S11.